Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells

다국어 초록 (Multilingual Abstract)

Purpose: To investigate the effect of combined inhibition of protein kinase B (AKT) and SRC on the growth and metastatic potentialof human pancreatic cancer cells.
Materials and Methods: AKT and SRC were inhibited using 10-DEBC and PP2, respectively. The expression of their messengerRNAs were down-regulated by specific small interfering RNA (siRNA). Changes in pancreatic cancer cell growth and metastaticpotential were determined using a cell viability assay and a xenotransplant model of pancreatic cancer, as well as cell migrationand invasion assays. Signal proteins were analyzed by Western blot.
Results: The inhibitors 10-DEBC and PP2 suppressed cell proliferation in a dose-dependent fashion in pancreatic cancer celllines MIA PaCa-2 and PANC-1. The simultaneous inhibition of AKT and SRC at low concentrations resulted in a significant suppressionof cell proliferation. Knockdown of AKT2 and SRC using siRNAs also significantly decreased cell proliferation. In a pancreaticcancer model, combined treatment with 10-DEBC and PP2 also significantly suppressed the growth of pancreatic cancer.
Application of 10-DEBC with PP2 significantly reduced the metastatic potential of pancreatic cancer cells by inhibiting migrationand invasion. The combined inhibition suppressed the phosphorylation of mTOR and ERK in pancreatic cancer cells.
Conclusion: Combined targeting of AKT and SRC resulted in a synergistic efficacy against human pancreatic cancer growth andmetastasis.

참고문헌 (Reference)

1 Duxbury MS, "siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity" 198 : 953-959, 2004

2 Summy JM, "c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK" 31 : 263-274, 2005

3 Choi JH, "Uridine triphosphate increases proliferation of human cancerous pancreatic duct epithelial cells by activating P2Y2 receptor" 42 : 680-686, 2013

4 Wheeler DL, "The role of Src in solid tumors" 14 : 667-678, 2009

5 Je DW, "The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion" 43 : 768-776, 2014

6 Engelman JA, "Targeting PI3K signalling in cancer: opportunities, challenges and limitations" 9 : 550-562, 2009

7 Chang YM, "Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530" 27 : 6365-6375, 2008

8 Bjorge JD, "Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line" 6 : e19309-, 2011

9 Irby RB, "Role of Src expression and activation in human cancer" 19 : 5636-5642, 2000

10 유지훈, "Role of Janus Kinase/Signal Transducers and Activators of Transcription in the Pathogenesis of Pancreatitis and Pancreatic Cancer" 거트앤리버 발행위원회 6 (6): 417-422, 2012

11 Lee DH, "Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells" 9 : 5668-5676, 2010

12 Altomare DA, "Perturbations of the AKT signaling pathway in human cancer" 24 : 7455-7464, 2005

13 Hidalgo M, "Pancreatic cancer" 362 : 1605-1617, 2010

14 Duxbury MS, "Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness" 23 : 5834-5842, 2004

15 Furukawa T, "Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside" 43 : 905-911, 2008

16 Nieto J, "Metastatic pancreatic cancer 2008: is the glass less empty?" 13 : 562-576, 2008

17 Ito H, "Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness" 134 : 221-226, 2003

18 Yezhelyev MV, "Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice" 10 : 8028-8036, 2004

19 Trevino JG, "Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model" 168 : 962-972, 2006

20 Roy SK, "Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer" 5 : 10-, 2010

21 Gallia GL, "Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells" 8 : 386-393, 2009

22 Trevino JG, "Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis" 65 : 7214-7222, 2005

23 Jaganathan S, "Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src" 333 : 373-381, 2010

24 Messersmith WA, "Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts" 8 : 1484-1493, 2009

25 Chen KF, "Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells" 68 : 6698-6707, 2008

26 Nagaraj NS, "Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth" 17 : 483-493, 2011

27 Squadroni M, "Chemotherapy in pancreatic adenocarcinoma" 14 : 386-394, 2010

28 Siegel RL, "Cancer statistics, 2015" 65 : 5-29, 2015

29 Rajeshkumar NV, "Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer" 15 : 4138-4146, 2009

30 Stathis A, "Advanced pancreatic carcinoma: current treatment and future challenges" 7 : 163-172, 2010

31 Choi JH, "Activating P2X7 receptors increases proliferation of human pancreatic cancer cells via ERK1/2 and JNK" 47 : 643-651, 2018

32 Tanno S, "AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells" 61 : 589-593, 2001

33 Renouf DJ, "A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer" 30 : 779-786, 2012